The company's technology, Duplex Sequencing, significantly improves the accuracy of DNA sequencing by over 10,000 fold, allowing detection of mutations that are invisible by other approaches. This technology has potential applications in various fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. TwinStrand Biosciences holds an exclusive worldwide license to develop and commercialize Duplex Sequencing. Their ultra-high accuracy, error-corrected sequencing method independently tracks both strands of individual DNA molecules, reducing error rates from 1-in-100 to 1-in-10 million, revealing ultra-low frequency variants. This offers highly sensitive and specific data that can inform critical decisions in clinical medicine, public health, and other fields of science on a faster timescale. TwinStrand Biosciences is committed to science first and aims to develop and deliver the unprecedented accuracy of TwinStrand Duplex Sequencing™ technology for applications in clinical medicine and life sciences where it can do the greatest good for the greatest number of people.